Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
Shah
N P
NP
Department of Medicine, University of California, Los Angeles 90095-1678, USA.
Sawyers
C L
CL
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D017321:Clinical Trials, Phase I as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005544:Forecasting; D018390:Gene Targeting; D016313:Genes, abl / Q000187:drug effects*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases